Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8430703 | Biology of Blood and Marrow Transplantation | 2017 | 26 Pages |
Abstract
- Intermediate monocytes are increased in patients with GVHD.
- Intermediate monocytes promote the induction of MDR1+Th17.1 cells.
- 1α,25-(OH)2D3 treatment of monocytes reduces prednisolone-induced MDR1+Th17.1 cells.
- JAK2 and CD74 expression is decreased in monocytes treated with 1α,25-(OH)2D3.
- Combination of 1α,25-(OH)2D3 and prednisolone might be promising for GVHD treatment.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Katharina Reinhardt-Heller, Insa Hirschberg, Peter Lang, Thomas Vogl, Rupert Handgretinger, Wolfgang A. Bethge, Ursula Holzer,